Giant Cell Carcinoma Research Articles

EP94 - Occurrence of Clavicle Tumors and its Surgical Outcome

Abstract Clavicle tumors have an occurrence of around 1% of all bone tumors. They have a very limited literature regarding their features and outcome which makes the treating physician face a big diagnostic obstacle. This study aims to provide a systematic review on the clinicopathological characteristics and the management outcome. Twenty seven cases of primary clavicle tumors were studied and analyzed during 2021-2023. All cases underwent the initial investigations and were confirmed on histopathology. The Age, sex, location, type and surgical outcome was analyzed and compared. Malignant tumors were found in 55.6%of the cases, 44.4% were benign. The histopathological types in this group were osteosarcoma(9 cases),giant cell tumour(6 cases),Ewing sarcoma(5 cases), Aneurysmal Bone Cyst(4 cases), Simple bone cyst(2 cases),Mixed fibroma(1 case). Majority were located in the sternal end and the middle area was the least. Complete or Partial Claviculectomy was done in all our cases. Resection of the medial end/partial claviculectomy was done in 66.6% of the total 18 cases and 33.33% of the cases were giant cell carcinoma (6 cases), no complications found post operatively. The patients were examined for functioning and adequacy of the involved limb and the end result of all were satisfactory. No patients had any limitations in their daily activities and all patients had a full range of motion. No neurovascular deficit was found. Reconstruction of any manner was not required following claviculectomy which is supported by the above assessed report. Our study also highlights that the dispersal of tumors in the clavicle is quite different as compared to long bone tumors.

Giant cell carcinoma of the urinary bladder

We present the clinicopathological features of 23 cases of the giant cell subtype of urothelial carcinoma, a rare subtype of bladder cancer recognized in the current World Health Organization classification of urological tumors. Histologically, the architectural pattern of the tumor varied from infiltrating to the solid expansile pleomorphic tumor with giant, bizarre, anaplastic cells. Typical or atypical mitotic figures were frequently present in all cases. Between 10 and 30% of the tumor had a giant cell component. All cases were associated with conventional high-grade urothelial carcinoma, with areas of squamous cell divergent differentiation and micropapillary carcinoma present in six and two cases, respectively. In one case each had sarcomatoid, nested, small cell, or glandular divergent differentiation. At diagnosis, 35% of patients had advanced disease and 12% had distant metastases. When comparing giant cell urothelial carcinoma with conventional urothelial carcinoma in a matched analysis, differences in overall and cancer-specific survival were observed, particularly in the T1 stage category. Immunohistochemical staining showed a similar profile of urothelial lineage with frequent positive expression of uroplakin II, GATA3, CK20, CK7, and S100P in both giant cell and conventional urothelial carcinomas. High Ki67 proliferation (range, 60–90%; mean, 71%) and nuclear p53 accumulation (mutant profile; range, 50–90%; mean, 64%) were observed. Using the 22C3 assay, the expression of PD-L1 was found to be variable in two cases, and beta-HCG was negative. In conclusion, giant cell carcinoma is a subtype of urothelial carcinoma associated with advanced clinical stage and a trend to lower survival rates.

Diagnostic Challenge: Keratocanthoma vs. Giant Palpebral Squamous Cell Carcinoma - A Case Study of the Boundary between Benign and Malignant

Diagnostic Challenge: Keratocanthoma vs. Giant Palpebral Squamous Cell Carcinoma - A Case Study of the Boundary between Benign and Malignant

Patent blue interferes with the measurement of lipemia index in a patient with sentinel lymph node.

Lipids interfere with absorbance measurements conducted using colorimetric methods. To monitor lipemia, some systems measure absorbance using an analyzer. This report describes a novel case of interference with the lipemia index without lipemia. A 64-year-old woman with giant basal cell carcinoma underwent resection and sentinel lymph node biopsy. The patient had been subcutaneously injected with patent blue during sentinel lymph node resection. After surgery, her serum and urine were yellow-green, and the lipemia index, calculated by measuring absorbance at 658 nm (main wavelength) and 694 nm (secondary wavelength) using a JCA-BM8040 chemistry analyzer, was high. The absorbance spectrum of the patient's serum and patent blue solution were compared to determine the cause of the high lipemia index. The patient's serum and the patent blue solution showed absorption at wavelengths between 540 and 698 nm. Moreover, the absorbance was concentration-dependent for patent blue. These results thus indicated that the patient's serum contained patent blue. Here, we report a case wherein patent blue affected the lipemia index. Thus, it must be noted that patent blue injection may yield inaccurate results when evaluating lipemia index.

Clinicopathologic and Molecular Characterization of Xanthomatous Giant Cell Renal Cell Carcinomas: Further Support for a Close Morphologic Spectrum to Eosinophilic Solid and Cystic Renal Cell Carcinomas.

A recent study described a rare subtype of tuberous sclerosis complex ( TSC )-mutated renal cell carcinoma primarily characterized by Xanthomatous giant cell morphology. Only 2 cases in young individuals have been reported so far, making the correct diagnosis challenging from a pathological perspective. It remains unknown whether this tumor represents an independent subtype or belongs to other TSC -mutated tumors. We conducted a clinicopathologic evaluation and immunohistochemical profiling of 5 cases of Xanthomatous Giant Cell Renal Cell Carcinoma (XGC RCC) with confirmed TSC2 mutations through targeted DNA sequencing. In addition, we analyzed transcriptomic profiles using RNA-seq for the following samples: XGC RCC, Low-grade Oncocytic tumors (LOT), High-grade Oncocytic tumors/Eosinophilic Vacuolar Tumors (HOT/EVT), Eosinophilic Solid and Cystic Renal Cell Carcinomas (ESC RCC), Chromophobe cell Renal Cell Carcinomas (ChRCC), Renal Oncocytomas (RO), clear cell Renal Cell Carcinomas (ccRCC), and normal renal tissues. There were 2 female and 3 male patients, aged 22 to 58 years, who underwent radical nephrectomy for tumor removal. The tumor sizes ranged from 4.7 to 9.5cm in diameter. These tumors exhibited ill-defined boundaries, showed an expansive growth pattern, and featured distinctive tumor giant cells with abundant eosinophilic to Xanthomatous cytoplasm and prominent nucleoli. All tumors had low Ki-67 proliferation indices (<1%) and demonstrated immune reactivity for CD10, PAX8, CK20, CathepsinK, and GPNMB. Next-generation sequencing confirmed TSC2 mutations in all cases. RNA sequencing-based clustering indicated a close similarity between the tumor and ESC RCC. One patient (1/5) died of an accident 63 months later, while the remaining patients (4/5) were alive without tumor recurrences or metastases at the time of analysis, with a mean follow-up duration of 43.4 months. Our research supports the concept that Xanthomatous giant cell renal cell carcinoma (XGC RCC) shares clinicopathological and molecular characteristics with ESC RCC and shows a relatively positive prognosis, providing further support for a close morphologic spectrum between the two. We propose considering XGC RCC as a distinct subtype of ESC RCC.

Effect of histological subtype on the efficacy of perioperative chemotherapy in pulmonary sarcomatoid carcinoma: a retrospective study based on SEER population.

The efficacy of perioperative chemotherapy (PC) in pulmonary sarcomatoid carcinoma (PSC) is controversial. We conducted this study to investigate the effect of different histological subtypes on the efficacy of PC in PSC patients. Clinicopathological data of 811 PSC patients of different histological subtypes were collected from the Surveillance, Epidemiology, and End Results (SEER) database. Kaplan-Meier method and log-rank test were used to evaluate the effects of PC on the overall survival (OS) and cancer-specific survival (CSS) in different subtypes of PSC patients. Propensity score matching (PSM) was used to reduce potential confounding effects. Subgroup analyses were conducted to further investigate the efficacy of PC in patients with different characteristics. A total of 210 (25.89%) enrolled PSC patients received PC. PC was not associated with OS or CSS benefit in pleomorphic carcinoma, giant cell carcinoma, or spindle cell carcinoma patients, neither before nor after matching. But survival benefit of PC was observed in carcinosarcoma patients both before (5-year OS: 48.79% vs. 38.75%, P=0.01) and after (5-year OS: 51.29% vs. 17.54%, P=0.003) matching. Subgroup analyses showed that in patients whose tumor larger than 4 cm, PC was still associated with improved survival in carcinosarcoma, but not in the other histological subtypes of PSC. The efficacy of PC varies between different subtypes of PSC. Survival benefit of PC was only observed in carcinosarcoma patients, but not in pleomorphic carcinoma, giant cell carcinoma, or spindle cell carcinoma patients. Histological subtype should be considered when treating PSC patients with PC.

Super giant basal cell carcinoma: a comprehensive systematic review.

Super giant basal cell carcinoma (SGBCC), defined as greater than 20cm in diameter, is a rare oncological entity, with scarce literature. The authors conducted a review to characterize SGBCC, specifically with regards to age, sex predilection, risk factors, geographical location, body site, metastasis, and treatment. A systematic literature search was conducted from 1972 to 2023. All abstracts, studies, and citations were reviewed. The initial result showed 47281 articles and were filtered down for human, skin, English language, and SGBCC. The authors identified 20 case reports for our analysis. The sample size was too small to conduct extensive statistical analysis. Majority of the cases were reported in North America and Europe. Males outnumbered almost females 2:1. The mean age was 61 years. The lesion was located on trunk in 16 out of 20 cases. In 13 out of 20 years, the lesion had been present for more than 10 years and 7 out of 20 cases reported metastasis. Several reports documented low socioeconomic status and poor mental health. Regarding treatment, 11 patients underwent surgery, radiation was utilized in 6 patients and immunotherapy (Vismodegib) in 4 patients. Although basal cell carcinoma (BCC) is known to have a favorable prognosis, SGBCC is highly aggressive with ability to metastasize. Our review reveals SGBCC is commonly diagnosed in males in their sixth decade, present for more than 10 years duration, risk factors include low socioeconomic status and poor mental health, commonly found on the trunk with a predilection for metastasis. The authors believe self-neglect is the likely etiology of the large size. Treatment options may be multimodal with a combination of surgery, radiation therapy or immunotherapy (Vismodegib).

Pembrolizumab-Induced Lichen Planus in a Patient with Metastatic Pulmonary Giant Cell Carcinoma: A Case Report and Literature Review

Ιmmune checkpoint inhibitors (ICIs) have revolutionized the management of advanced cancers. Nevertheless, the oncologic response is often achieved at the cost of immune-related adverse events (irAEs). We present a case of an immune-mediated lichen planus (LP) and a literature review of similar cases. A 60-year-old man, who is being treated with pembrolizumab for a pulmonary giant cell carcinoma since April 2022, presented in November 2022 with a pruritic eruption that appeared two weeks ago. Examination showed bright purple confluent scaly papules on wrists, proximity of limbs, back and buttocks and palmar keratoderma made of violaceus papules covered with reticular white striae. Histological examination revealed an epidermal hyperplasia, vacuolization of the basal layer, necrotic keratinocytes and a band-like subepidermal lymphocytic infiltrate with many eosinophils. The diagnosis of an immune-related LP was retained. Pembrolizumab was withheld because of the severity and the extension of the lesions. Superpotent topical steroids were prescribed with a significant improvement of the rash within 3 weeks. Immune-mediated lichenoid euptions represent one of the most frequent dermatologic irAEs. In our patient, the onset seven months after the initiation of ICIs, the infiltrate rich in eosinophils, and the rapidly diffused character are indications of an immuno-mediated LP.

Giant cutaneous squamous cell carcinoma

Cutaneous squamous cell carcinoma is the second most common type of skin cancer after basal cell carcinoma [1]. Of all non melanoma skin cancers, it accounts for 20% to 25% and its mortality is up 1.5 to 3.4% [2]. SCC is considered very high risk if it is a tumor ≥4 cm, in any location. In these cases, surgery remains the first-line and most effective treatment.

Giant neglected unresectable ulcerated basal cell carcinoma of face: Radiotherapy at rescue

Abstract Basal cell carcinomas are typically considered indolent and slowly progressing tumors, but giant basal cell carcinomas are more aggressive with more risk of invasion and poor prognosis. management of such giant BCCs is difficult due to difficulty in surgical approach. we hereby reporting a case of giant ulcerated BCC of face treated with radiotherapy as a rescue treatment.

Locally aggressive giant basal cell carcinoma of the head with focus on surgical treatment - a case report

Introduction: Basal cell carcinoma is the most common non melanoma skin cancer. It accounts for approximately 80% of all skin cancers. Case report: We presented a 62-year-old patient with a giant, deeply infiltrative, destructive lesion of the head which lasted for 15 years. Microbiological analysis showed contamination, computed tomography (CT) scan showed deep infiltration and bone destruction. The risks of operative treatment were numerous. The treatment was more complicated by infection, infiltrative spreading and the patient's comorbidity. Regardless, we decided on a wide surgical resection with pathohistological evaluation of the resection margins. The patient denied oncological treatment. After 10 years, there were no recurrent tumours. Conclusion: Aggressive surgical treatment is the treatment of choice for giant basal cell carcinoma. In the case of giant locally aggressive and advanced neoplasms, when surgery is not appropriate or not possible, medical treatment becomes oncological.

Aumolertinib: effective treatment for asymptomatic pulmonary giant cell carcinoma with EGFR L858R mutation - a case report

Aumolertinib, as a novel third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), has been widely employed as a first-line treatment for advanced non-small cell lung cancer (NSCLC) patients with EGFR mutation. However, reports regarding the benefit of using aumolertinib as a monotherapy in pulmonary giant cell carcinoma are relatively scarce. In this report, we present a pulmonary giant cell carcinoma case harboring the EGFR Leu858Arg (L858R) mutation, with the patient at stage cT2bN3M1c IVB. Through the use of autolearning as a single agent, we effectively controlled the progression of pulmonary giant cell carcinoma, achieving a 6-month progression-free survival during the treatment course. Notably, the patient’s tumor not only ceased its growth but also continued to shrink, highlighting a significant therapeutic effect. This case reveals the effectiveness of aumolertinib as a monotherapy in controlling disease progression. The finding underscores the therapeutic advantage of aumolertinib in this particular subgroup of patients, offering a novel treatment option for pulmonary giant cell carcinoma.

Giant renal cell carcinoma in a patient with ipsilateral lower limb hypertrophic lichen planus; Case report and literature review

Giant renal cell carcinoma in a patient with ipsilateral lower limb hypertrophic lichen planus; Case report and literature review

Clinicopathological features and differential diagnosis of gastric pleomorphic giant cell carcinoma.

The aim of this study was to investigate the clinicopathological features and differential diagnosis of gastric pleomorphic giant cell carcinoma. Histopathology, immunohistochemistry, and human epidermal growth factor receptor 2 (HER2) gene testing were conducted for seven cases of gastric pleomorphic giant cell carcinoma. In histomorphological terms, all seven cases involved pleomorphic giant cell carcinoma, accounting for more than 10% of the entire tumor, with pleomorphic spindle cells and giant cells mixed with various histomorphological structures of adenocarcinoma with high, intermediate, and low differentiation. There was large heterogeneity in the HER2 protein expression and HER2 gene amplification in the gastric pleomorphic giant cell carcinoma, and both levels of HER2 were focal in three cases, accounting for 42.9% (3/7). The mismatch repair gene proteins MLH1, MSH2, PMS2, and MSH6 were positive. Routine immunohistochemical markers, i.e., pan-cytokeratin, epithelial membrane antigen, villin, caudal-type homeobox 2, E-cadherin, and p53, were positive in the gastric pleomorphic giant cell carcinoma, while vimentin, calponin, smooth muscle actin, nestin, S-100, cluster of differentiation (CD) 99, desmin, and CD34 were focally expressed in both the spindle and the giant cells, with Ki-67-positive cells accounting for 70-80%. Gastric pleomorphic giant cell carcinoma presents multiple histomorphological features and is easily confused with various tumors. Clarifying the histopathological features of this type of tumor is important for differential diagnosis and precise treatment.

Giant cell carcinoma of the lung with hypertrophic pulmonary osteoarthropathy as a paraneoplastic syndrome: a case report

BackgroundHypertrophic pulmonary osteoarthropathy is a rare syndrome characterized by a triad that includes periostitis, digital clubbing, and painful arthropathy of the large joints, especially large joints in the lower limbs with lung cancer. Herein we describe a case of a giant cell carcinoma of the lung with hypertrophic pulmonary osteoarthropathy as a paraneoplastic syndrome. The tumor was successfully resected, and complete remission of the syndrome was achieved after surgery.Case presentationA 48-year-old man with right fingers and bilateral ankle arthralgias was referred to our hospital. These arthropathies were painful and refractory to the oral administration of several non-steroidal anti-inflammatory drugs; thus, oxycodone hydrochloride hydrate was prescribed. Additionally, the fingers and toes had a clubbed appearance and the tubular bones were shown as double lines on radiographs of both arms and legs, indicating periosteal thickening. A 45-mm mass-like shadow was present on the right upper-to-middle lung field on the chest x-ray, which was confirmed to be a mass in the upper lobe of the right lung on the chest CT scan. An abnormal uptake was observed in the area of the mass on the FDG-PET scan; the standardized uptake value maximum was 11.8. The histologic diagnosis of a bronchoscopic biopsy was an undifferentiated carcinoma, and the clinical diagnosis was non-small cell lung cancer. The clinical stage was c-T2bN0M0 with paraneoplastic syndrome as a hypertrophic pulmonary osteoarthropathy. A right upper lobectomy with an S6 partial resection adjacent to the upper lobe of the right lung and an ND2a-2 lymph node dissection was performed. The postoperative course was uneventful. The pathologic diagnosis was a giant cell lung carcinoma, which was classified as p-T3 (52 mm in diameter) N0M0, stageIIB. A gradual decrease in arthritic pain was observed from the first operative day. No anodyne, including oxycodone, was required approximately 2 months after surgery. No tumor or paraneoplastic syndrome recurrence was observed 2 years postoperatively.ConclusionsHypertrophic pulmonary osteoarthritis may occur as a secondary manifestation of lung malignancies. Thus, the paraneoplastic syndrome should be considered in such cases.

Primary Pulmonary Carcinomas with Spindle and/or Giant Cell Features: A Review with Emphasis in Classification and Pitfalls in Diagnosis.

Primary carcinomas of the lung are vastly represented by the conventional types of adenocarcinomas or squamous cell carcinomas. However, there are other types of non-small cell carcinomas that although uncommon represent a meaningful group that often pose a problem not only in diagnosis but also in classification. Spindle cell and/or giant cell carcinomas, although uncommon represent an important group of primary lung carcinomas. Important to highlight is that current criteria are rather ambiguous and likely not up to date, which renders the classification of these tumors somewhat more obscure. In addition, with the daily use of immunohistochemical stains, the classification of these tumors may also pose a different problem in the proper allocation of these tumors. Proper classification is highly important in the selection process that takes place using such material for molecular analysis. The current molecular characteristics of these tumors are limited and lack more in-depth studies and analyses that can provide specific targets for the treatment of patients with these tumors. The current review attempts to highlight the shortcomings in the current classification and definitions of these neoplasms as well as the more current view regarding these tumors when the use of immunohistochemical stains is employed.

Open Partial Nephrectomy in Giant Papillary Renal Cell Carcinoma: Presentation of 2 Cases

Open Partial Nephrectomy in Giant Papillary Renal Cell Carcinoma: Presentation of 2 Cases

Giant nodular basal cell skin cancer

The article presents clinical case report of primary giant nodular basal cell skin cancer in two patients at the age of 64 and 68 years and with disease duration of 20 and 15 years respectively. Psychological status of fear and anxiety are considered the main reasons for the late health encounter.&#x0D; The clinical picture of the case report was characterized by a slow long-term asymptomatic growth of solitary tumor-like mushroom-shaped nodes of stagnant pink color with a bumpy surface, densely elastic consistency, adherent to underlying soft tissues and sized 9.5 7.0 cm and 5.0 9.0 cm respectively. Giant basaliomas were located on the scalp in a woman and on the trunk skin in a man. The clinical tumors features are corresponded to those of a large conglomerated basal cell skin cancer. The article also presents a description of the clinical and dermatoscopic picture of giant nodular basaliomas.&#x0D; The patients underwent curative surgical excision of tumors with pathomorphological examination of the postoperative material. The histological picture of giant basal cell carcinoma in both cases is represented by tumors of a complex structure, namely a solid adenoid type with invasion into the reticular dermis and subcutaneous fat. The low biological potential of giant nodular basaliomas has been established.

Giant basal cell carcinoma of the skin: Report of two cases

Giant basal cell carcinoma of the skin: Report of two cases

Giant basal cell carcinoma of the scalp: rotation advancement flap as a successful dermatosurgical approach.

Giant keratinocyte tumors, in particular basal cell carcinomas of the scalp area, are a serious challenge for dermatosurgeons, oncologists, and maxillofacial and reconstructive surgeons. The scalp area is limited in terms of skin mobility, and its elasticity decreases with age. The size of the tumors in this area and the degree of infiltration of the underlying tissues are important for the therapeutic choice, from surgical removal, waiting for granulations to form, and placing a split skin mesh graft (at a later stage) to performing complex rotational/transpositional or advancement flaps. Achieving an optimal aesthetic result is often the consequence of interventions carried out or based on the decisions of multidisciplinary teams. Alternatives, such as radiotherapy and targeted therapy with vismodegib, could be administered both preoperatively and postoperatively or as first-line therapy, depending on the tumor board decisions. We present the case of a 69-year-old female patient with a histopathologically proven preoperative giant basal cell carcinoma of the scalp that did not infiltrate the tabula externa. A preoperative ultrasound was performed to preserve the feeding flap arteries. Surgical treatment under general anesthesia was planned and subsequently carried out. During surgery, the surgical resection lines were in close proximity to the arterial vessels, but they remained preserved and ensured a subsequently unproblematic healing process. After the application of the rotational advancement flap technique under general anesthesia, an optimal cosmetic effect was achieved.